AssayIndex
Physical tests

Forced degradation and stability-indicating capability

Deliberately damaging a sample to prove the method can see damage — and what the resulting degradant profile says about storage.

method reference3 sections4 pharmacopoeial references

A purity method that cannot separate a compound from its degradation products is not stability-indicating, and a stability claim made with a non-stability-indicating method is worthless. Forced degradation is how you find out which you have.

Stress conditions

StressConditionExpected degradants in peptides
Acid hydrolysis0.1 M HCl, 60 °C, 2–24 hBackbone cleavage at Asp-Pro; pyroglutamate ring opening; ethylamide/amide hydrolysis
Base hydrolysis0.1 M NaOH, 25 °C, 1–8 hAspartimide and β-Asp; deamidation; lipid-side-chain amide hydrolysis; racemisation
Oxidation0.3–3 % H₂O₂, 25 °C, 1–24 hMet sulfoxide then sulfone; Trp oxindole and kynurenine; His 2-oxo-His; Cys to sulfonic acid
Thermal60–80 °C, dry, 1–14 dAggregation; deamidation; diketopiperazine from N-terminal Pro
PhotolyticICH Q1B option 2, 1.2 M lux·h + 200 W·h/m² UVTrp and Tyr oxidation; cis/trans isomerisation in the non-peptide adjuncts
Reduction5 mM DTT or TCEP, 25 °C, 30 minOpen-chain form of every disulfide-containing compound
Freeze–thaw5 cycles, −20 °C to 25 °CAggregation; particulate formation

The target is 5–20 % degradation. Below that the degradants may not be detectable; above it, secondary degradation products of the primary degradants confuse the picture and the mass balance stops closing.

Demonstrating stability-indicating capability

  1. Each major degradant must be resolved from the main peak with R ≥ 1.5, and from each other where possible.
  2. Peak purity of the main peak by PDA or MS must be maintained in every stressed sample — no degradant hiding underneath it.
  3. Mass balance must close: the sum of the remaining main peak and all degradants should account for 95–105 % of the initial main-peak area, allowing for response-factor differences.
  4. The method must show no interference from the diluent, the stress reagent, or the neutralisation.

What forced degradation tells the index

Two useful things. First, it identifies each compound's degradation pathways, which is what the "known degradants" field on every compound page records — and that in turn is what allows a submitted impurity to be classified as a storage finding rather than a synthesis finding. A des-Gly deletion sequence does not form in a vial; a methionine sulfoxide does. That distinction determines whether a poor result is the supplier's problem or the shipping route's.

Second, it sets the expectation for what a stressed lot looks like. When a submitted report shows a degradant profile matching a known oxidative pathway with nothing else out of place, the most likely explanation is exposure rather than manufacture, and the index says so on the record.

Normative references

Cited because they are the documents the acceptance criteria above are taken from. The index applies them as written and states every deviation.

  • ICH Q1A(R2) — Stability testing of new drug substances and products
  • ICH Q1B — Photostability testing
  • ICH Q2(R2) — Validation of analytical procedures, specificity
  • Ph. Eur. 5.10 — Control of impurities

Related methods

Related-substances profiling

Naming impurities instead of totalling them: what it enables, how assignment works, and why an impurity fingerprint identifies a bulk.

Chromatographic purity

Method validation to ICH Q2(R2)

The eight validation characteristics, what each one demonstrates, and which of them the reports in this index actually document.

Quality system